CN106573017B - 用于治疗脓毒症的间充质基质细胞 - Google Patents

用于治疗脓毒症的间充质基质细胞 Download PDF

Info

Publication number
CN106573017B
CN106573017B CN201580042833.7A CN201580042833A CN106573017B CN 106573017 B CN106573017 B CN 106573017B CN 201580042833 A CN201580042833 A CN 201580042833A CN 106573017 B CN106573017 B CN 106573017B
Authority
CN
China
Prior art keywords
cells
mscs
cell
sepsis
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580042833.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573017A (zh
Inventor
维尔弗里德·达尔曼斯
埃莱乌特里奥·隆巴尔多
罗伯特·德克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of CN106573017A publication Critical patent/CN106573017A/zh
Application granted granted Critical
Publication of CN106573017B publication Critical patent/CN106573017B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
CN201580042833.7A 2014-06-30 2015-06-30 用于治疗脓毒症的间充质基质细胞 Active CN106573017B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14175095.0 2014-06-30
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (2)

Publication Number Publication Date
CN106573017A CN106573017A (zh) 2017-04-19
CN106573017B true CN106573017B (zh) 2021-06-11

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580042833.7A Active CN106573017B (zh) 2014-06-30 2015-06-30 用于治疗脓毒症的间充质基质细胞

Country Status (14)

Country Link
US (2) US20170151284A1 (enExample)
EP (1) EP3160481B1 (enExample)
JP (1) JP6722599B2 (enExample)
KR (1) KR102213527B1 (enExample)
CN (1) CN106573017B (enExample)
AU (1) AU2015283662B2 (enExample)
BR (1) BR112016030758B8 (enExample)
CA (1) CA2953884C (enExample)
IL (1) IL249814B (enExample)
MX (1) MX381544B (enExample)
NZ (1) NZ727950A (enExample)
RU (1) RU2715866C2 (enExample)
SG (1) SG11201610844PA (enExample)
WO (1) WO2016001846A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6714932B2 (ja) * 2015-12-01 2020-07-01 株式会社ＡｄｉｐｏＳｅｅｄｓ 脊椎動物の脂肪組織由来間葉系細胞株の製造方法
US11701389B2 (en) 2016-03-09 2023-07-18 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN110520138A (zh) 2017-02-28 2019-11-29 洛林大学 从华顿氏胶获得的用于治疗脓毒症的间充质干细胞
US11524000B2 (en) 2017-10-26 2022-12-13 Emory University Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
KR20250160527A (ko) * 2018-06-05 2025-11-13 메디포스트(주) 히알루론산과 줄기세포를 포함하는 연골손상 관련 질환 치료용 약학 조성물
ES2962812T3 (es) * 2018-10-29 2024-03-21 Ottawa Hospital Res Inst Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos
EP4098267A4 (en) * 2020-01-30 2024-03-06 JCR Pharmaceuticals Co., Ltd. MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP
US20240226173A1 (en) * 2021-05-13 2024-07-11 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2010015929A3 (en) * 2008-08-04 2010-04-29 Cellerix Sa Uses of mesenchymal stem cells
CN103648509A (zh) * 2011-03-11 2014-03-19 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307550A (pt) 1992-12-02 1999-05-25 Shell Int Research Composto fungicida processo para a preparação de um composto fungicida composição fungicida processo de combate aos fungos em um local e uso
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0832271B8 (en) 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2010015929A3 (en) * 2008-08-04 2010-04-29 Cellerix Sa Uses of mesenchymal stem cells
CN103648509A (zh) * 2011-03-11 2014-03-19 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
人脐带间充质干细胞对炎症性肠病小鼠模型的治疗作用;葛翠翠等;《生物技术通讯》;20141231;第25卷(第6期);813-816 *
脓毒症的免疫治疗进展;白冰心等;《中国新药与临床杂志》;20150331;第34卷(第3期);161-165 *

Also Published As

Publication number Publication date
US20200376038A1 (en) 2020-12-03
RU2016151738A3 (enExample) 2019-01-30
US20170151284A1 (en) 2017-06-01
BR112016030758A2 (enExample) 2017-08-22
BR112016030758B8 (pt) 2022-10-25
IL249814A0 (en) 2017-03-30
IL249814B (en) 2020-02-27
JP6722599B2 (ja) 2020-07-15
MX2017000142A (es) 2017-07-28
EP3160481B1 (en) 2020-09-09
MX381544B (es) 2025-03-12
CA2953884C (en) 2022-12-06
AU2015283662B2 (en) 2020-09-24
RU2715866C2 (ru) 2020-03-03
WO2016001846A1 (en) 2016-01-07
EP3160481A1 (en) 2017-05-03
KR102213527B1 (ko) 2021-02-09
CN106573017A (zh) 2017-04-19
RU2016151738A (ru) 2018-07-30
KR20170021343A (ko) 2017-02-27
AU2015283662A1 (en) 2017-01-19
SG11201610844PA (en) 2017-01-27
JP2017520583A (ja) 2017-07-27
NZ727950A (en) 2022-07-01
CA2953884A1 (en) 2016-01-07
BR112016030758B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
CN106573017B (zh) 用于治疗脓毒症的间充质基质细胞
US20220088084A1 (en) Uses of mesenchymal stem cells
JP6764912B2 (ja) 免疫調節活性を有する細胞集団、その調製方法および使用
EP3160480A1 (en) Mesenchymal stromal cells for treating rheumatoid arthritis
Delgado et al. Uses of mesenchymal stem cells
AU2015268704B2 (en) Uses of mesenchymal stem cells
HK1230927A1 (en) Uses of mesenchymal stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220406

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Madrid

Patentee before: TIGENIX S.A.U.

TR01 Transfer of patent right